AzTrials
AzTrials

Diffuse Large Cell LymphomaPhase 2NCT00591630

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

A Phase 2 study testing Zevalin, Carmustine and Etoposide in people with Diffuse Large Cell Lymphoma and Lymphoma, run by M.D. Anderson Cancer Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more effective than the combination of BEAM and rituximab alone in patients with lymphoma who receive a stem cell transplant. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Diffuse Large Cell Lymphoma, Lymphoma
What is being tested?
Zevalin, Carmustine and Etoposide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited States
Study dates
14 Nov 2007to 5 Mar 2020
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Relapsed CD20-positive B-cell diffuse large cell lymphoma (demonstrated in lymph nodes or bone marrow), chemosensitive (at least PR).
  • Age: up to 18-70 years of age.
  • Prestudy performance status of 0, 1, or 2 according to the WHO.
  • No anti-cancer therapy started within three weeks, prior to study initiation, and fully recovered from all toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy. No prior rituximab within three weeks of starting therapy.
  • If patients had prior radiation, this should have not involved more than 25% of the bone marrow.
  • Acceptable hematologic status within two weeks prior to patient registration, including: Absolute neutrophil count ({segmented neutrophils + bands} x total WBC) > 1,500/mm³ and platelet counts > 80,000/mm³
Show all 12Show fewer
  • IRB -approved signed informed consent.
  • Patients determined to have <10% bone marrow involvement with lymphoma within 60 days before study entry as defined by bone marrow aspirates and biopsies.
  • Female patients included must not be pregnant or lactating.
  • Patients should have at least 4-6 x 10^6 CD34+/kg peripheral stem cells collected. Around 1-2 million cells will beheld as back up.
  • Voluntary signed, written IRB-approved informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  • Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study.

Who cannot join

  • Failed stem cell collection of >/= 4x10^6CD34+/kg.
  • Prior radioimmunotherapy.
  • Presence of active CNS lymphoma.
  • Patients with abnormal liver function: total bilirubin > 1.5 mg/dl.
  • Patients with abnormal renal function: serum creatinine > 1.6 mg/dl.
  • Serious nonmalignant disease or infection which, in the opinion of the investigator and/or the sponsor, would compromise other protocol objectives.
Show all 20Show fewer
  • Corrected DLCO < 50% and FEV subscript 1 or FVC < 50% predicted.
  • Cardiac EF < 50% by 2-D Echogram.
  • Prior radiation to lungs.
  • Abnormal cytogenetics predictive of secondary cancers, such as -5,-7.
  • Pregnant (Positive Beta HCG test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
  • Patients with other malignancies diagnosed within 2 years prior to Study entry (except skin squamous or basal cell carcinoma).
  • Active uncontrolled bacterial, viral fungal infections.
  • Major surgical procedure or significant traumatic injury within 4 weeks prior to Study entry.
  • Serious, non-healing wound, ulcer, or bone fracture.
  • History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 3 months prior to Study entry.
  • History of Stroke within 6 months.
  • Myocardial infarction within the past 6 months prior to Study Day 1, or has New York Heart Association (NYHA) Class III or IV heart failure or arrythmias, unstable angina, uncontrolled congestive heart failure or arrythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by investigator as not medically relevant.
  • Uncontrolled chronic diarrhea.
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas

The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more effective than the combination of BEAM and rituximab alone in patients with lymphoma who receive a stem cell transplant.

Read the detailed description

The Study Drugs:

90Y Zevalin is designed to attach to lymphoma cells, and destroy the cells using a radiation particle that is attached to it.

111In Zevalin is like 90Y Zevalin, but the radioactive particle that is attached to it does not kill lymphoma cells. The radioactive particle makes the drug able to be seen inside your body. It is being used in this study to predict how fast the study drug will travel in the body and how long the drug stays in the body.

Carmustine, etoposide, cytarabine, and melphalan (BEAM) are designed to kill lymphoma cells by damaging the cells DNA.

Rituximab is designed to attach to lymphoma cells, which may cause them to die.

Study Groups 1 and 2:

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the toss of a coin) to 1 of 2 groups. You will have an equal chance of being assigned to each group. Group 1 will receive 90Y Zevalin along with rituximab and BEAM therapy. Group 2 will receive rituximab and BEAM therapy. You and the study staff will know which group you are in.

Study Drug Administration:

If you are in Group 1, you will receive rituximab through a needle in your vein (over 4-5 hours) followed by 111In Zevalin by vein (over 15 minutes). A nuclear scan will be done within the following 40 to 48 hours to see how the drug is traveling through your body.

If intolerable side effects are not shown by the scans, you will receive rituximab (over 4-5 hours) and 90Y Zevalin (over 15 minutes) through a needle in your vein 7 days after the 111In Zevalin infusion.

You will begin BEAM chemotherapy 7 days after the second 90Y Zevalin infusion.

BEAM Chemotherapy:

Both groups will have 7 days of BEAM combination chemotherapy.

  • On Day 1, you will receive carmustine through a needle in your vein over 1 hour.
  • On Days 2-5 you will receive cytarabine by vein (over 1 hour) followed by etoposide (over 3 hours). Both infusions will be repeated every 12 hours on Days 2-5.
  • On Day 6 you will be given melphalan by vein over 30 minutes.
  • On Day 7 the stem cells that were collected earlier from you will be given back ("transplanted") through a catheter over 30-45 minutes.
  • You will also receive rituximab by vein (over 5-7 hours) on Day 8.

You will receive rituximab (over 4-5 hours) 7 days after the stem cell transplant. You will receive G-CSF by injection once a day starting 7 days after the stem cell transplant until your blood counts return to a normal level. You should stay in the Houston area for about 2-4 weeks after the transplant.

Study Procedures:

At about 1 month after the transplant you will have x-rays, CT scans, and positron emission tomography (PET) scans. You will also have a bone marrow aspirate and biopsy to check the status of the disease.

Blood (about 1 tablespoon) will be drawn once a day while you are in the hospital to check your blood counts.

Blood tests (about 1-2 tablespoons), urine tests, bone marrow collections, and x-rays may be done as needed to track the effects of the transplant.

You will have transfusions of blood and platelets as needed.

Study Groups A and B:

About 1 month after the transplant, you will be randomly assigned (as in the toss of a coin) to 1 of 2 new groups (Group A and Group B). Group A will receive rituximab by vein over 5-7 hours, once every 3 months, starting 3 months after the stem cell transplant. You will receive rituximab for the first 18 months after the stem cell transplant. Group B will not receive rituximab. You will have an equal chance of being in each group.

Follow-up Visits:

You will return to the clinic every 6 months for 5 years to check the status of the disease. The following tests and procedures will be performed:

  • Blood (about 1-2 tablespoons) and urine will be collected for routine tests.
  • You will have a bone marrow biopsy to check the status of the disease.
  • You will have a chest x-ray and a CT scan.
  • You will have a PET scan.

Length of Study:

You may stay on study as long as you are benefitting. You will be taken off-study if the disease gets worse or intolerable side effects occur.

This is an investigational study. 90Y-Zevalin is approved by the FDA for relapsed and refractory lymphoma. Its use in this study is investigational. 111In Zevalin, Carmustine, etoposide, cytarabine, melphalan, and Rituximab are all FDA approved and commercially available. However, their use together in this study is also investigational. Up to 50 patients will be take part in this study. All will be enrolled at MD Anderson.

Being tested
Zevalin, Carmustine, Etoposide, Cytarabine, Melphalan
Keywords
Diffuse Large Cell Lymphoma, Lymphoma, Zevalin, Ibritumomab, IDEC-Y2B8, Carmustine, BCNU, BiCNU, Etoposide, VePesid, Cytarabine, Ara-C, Cytosar, DepoCyt, Cytosine arabinosine hydrochloride, Melphalan, Rituximab, Rituxan, BEAM
Medical subject headings
Lymphoma, Large B-Cell, Diffuse, Lymphoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ZevalinDrug

    Also called Ibritumomab, IDEC-Y2B8

    (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.

  • CarmustineDrug

    Also called BCNU, BiCNU

    300 mg/m^2 by vein.

  • EtoposideDrug

    Also called VePesid

    200 mg/m^2 by vein every 12 hours.

  • CytarabineDrug

    Also called Ara-C, Cytosar, DepoCyt, Cytosine arabinosine hydrocholoride

    200 mg/m^2 by vein every 12 hours.

  • MelphalanDrug

    140 mg/m^2 by vein.

  • RituximabDrug

    Also called Rituxan

    Arm 1, Arm 2 = 250 mg/m^2 by vein;

    Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;

    Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

  • Stem Cell TransplantProcedure or surgery

    Also called Stem Cell Transplantation, SCT

    Injection of stem cells (Autologous SCT)

Study groups in NCT00591630
Study groupRoleWhat they receive
Zevalin + BEAM + Rituximab +Stem Cell Transplant + RituximabActive comparatorZevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
Receives: Drug: Zevalin; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Rituximab; Procedure: Stem Cell Transplant
Zevalin + BEAM + Rituximab +Stem Cell TransplantActive comparatorZevalin + BEAM + Rituximab Followed by Stem Cell Transplant
Receives: Drug: Zevalin; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Rituximab; Procedure: Stem Cell Transplant
BEAM + Rituximab + Stem Cell Transplant + RituximabActive comparatorBEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
Receives: Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Rituximab; Procedure: Stem Cell Transplant
BEAM + Rituximab + Stem Cell TransplantActive comparatorBEAM + Rituximab Followed by Stem Cell Transplant
Receives: Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Rituximab; Procedure: Stem Cell Transplant

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With a 2-Year Progression-Free Survival (PFS)

    Response evaluated using the standard criteria response for lymphoma through CT scan.

    Measured: 2 years (beginning day 30 after treatment)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jan 2008 (estimated)
  2. Study start14 Nov 2007
  3. Primary completion5 Mar 2020
  4. Study completion5 Mar 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00591630
Sponsor's protocol ID
2006-1018
Other IDs
NCI-2012-01753
Status last verified
Jan 2021
First submitted
27 Dec 2007
Last updated
2 Feb 2021
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Zevalin, Carmustine and Etoposide in people with Diffuse Large Cell Lymphoma and Lymphoma, run by M.D. Anderson Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Feb 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With a 2-Year Progression-Free Survival (PFS) (time frame: 2 years (beginning day 30 after treatment)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00591630.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2021.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in